SESSION-1 BENCHMARKS AND EARLY DETECTION

Chairmen: Stanley B. Kaye, The Royal Marsden NHS, London, United Kingdom
Andreis Cesano, Hospital Clinico Universitario, Valencia, Spain

08:45-09:05 Prognostic profiling
Elke C. Goett, National Cancer Institute, Bethesda (Maryland), USA

09:05-09:25 Biological markers
Robert Bast Jr, MD Anderson Cancer Center, Houston (Texas), USA

09:25-09:45 Screening programs
Ian Jacobs, Institute for Women’s Health, London, United Kingdom

09:45-10:00 Discussion

10:00-10:20 Laparoscopy vs. Laparotomy in early ovarian cancer
Fabio Greco, University of Bari, Bari, Italy

10:20-10:40 Prognostic factors for complete debulking in 1st and 2nd line
Phil Harvey, Dr. Nord Schmalfels-Klinik, Weibden, Germany

10:40-11:00 Ir-Stage IIIc ovarian cancer: a separate entity?
Jonathan J. Berek, Stanford University School of Medicine, Stanford (California), USA

11:00-11:20 Discussion

11:20-11:40 Coffee Break

SESSION-2 SURGICAL ISSUES

Chairmen: Nepea F. Maceser, Royal Hospital for Women, Sydney, Australia
Enrique Garcia, Hospital Clinico de Oncologia, Valencia, Spain

10:00-10:20 Uptrend chemotheraphy vs. surgery
Daniele Persan, University of Trieste, Trieste, Italy

10:20-10:40 New markers for response
Richard Maris, University of Pennsylvania, Philadelphia, USA

10:40-11:00 Pharmacogenetic assessment of toxicity and outcome after platinum-based therapy in ovarian cancer
Lloyd Paul, Genomics Research Centre, Montreal (Quebec), Canada

11:00-11:20 Discussion

11:20-11:40 Lunch

SESSION-3 PRIMARY OVARIAN CANCER

Chairmen: Paolo Francia, Fondazione-Centro, Modena, Italy
Antonio Casado, Hospital Clinico San Carlos, Madrid, Spain

12:00-12:20 Uptrend chemotherapy vs. surgery
Daniele Persan, University of Trieste, Trieste, Italy

12:20-12:40 New markers for response
Richard Maris, University of Pennsylvania, Philadelphia, USA

12:40-13:00 Pharmacogenetic assessment of toxicity and outcome after platinum-based therapy in ovarian cancer
Lloyd Paul, Genomics Research Centre, Montreal (Quebec), Canada

13:00-13:20 Discussion

13:20-13:45 Lunch

SESSION-4 RECURRENT OVARIAN CANCER

Chairmen: Antonio González, MD Anderson International, Madrid, Spain

15:00-15:20 Optimizing management
Daniele Persan, University of Trieste, Trieste, Italy

15:20-15:40 Symptom control
Michael Greco, National Cancer Institute, Bethesda (MD), USA

15:40-16:00 Angiogenesis inhibition
Bradley Marks, MD Anderson Cancer Center, Houston (Texas), USA

16:00-16:20 Other new targets
Andrea M. Quer, Dana-Farber Cancer Institute, Boston (Massachusetts), USA

16:20-16:45 Discussion

16:45-17:15 Coffee Break

SESSION-5 TRIALS WITH IMPACT ON CLINICAL MANAGEMENT

Chairmen: Elisabeth Edelmaier, NCIC Clinical Trials Group, Kingston (Ontario), Canada
Eric Pi-Jade LaRue, Hopital Pitie-Salpetriere, Paris, France

17:15-17:45 First-line
Michael A. Bockman, Fox Chase Cancer Center, Philadelphia, USA

17:45-18:15 Second-line
Bradley J. Marks, MD Anderson Cancer Center, Houston (Texas), USA

18:15-18:35 I.P. Therapy
Jan B. Verweij, Erasmus University Hospital, Rotterdam, Netherlands

18:35-18:50 Discussion

REMARKS AND CONCLUSIONS

18:50-19:00 Andrea Poveda, Instituto Valenciano de Oncologia, Valenica, Spain